Clinical trial
Comparison of GSKBiologicals' Hib-MenCY-TT Vaccine vs Licensed Hib Conjugate or…
NCT00129129 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00129129 |
|---|---|
| Title | Comparison of GSKBiologicals' Hib-MenCY-TT Vaccine vs Licensed Hib Conjugate or Meningococcal Vaccine |
| Official title | Evaluate Immuno and Safety of GSKBiologicals' HibMenCYTT vs Licensed Hib Conjugate Vaccine, Each Coadministered With Pediarix® and Prevnar®, in Healthy Infants. An Exploratory Control Group Will Receive Licensed Menomune® at 3 to 5 Years |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Haemophilus Influenzae Type b, Neisseria Meningitidis |
| Intervention type | Biological |
| Interventions | GSK Biologicals' Haemophilus influenza type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine 792014 vaccine, ActHIB, Pediarix, Prevnar, Menomune |
| Enrollment | 756 |
| Start date | Aug 1, 2004 |
| Primary completion | Sep 15, 2005 |
| Completion | Mar 29, 2006 |
| First posted | Aug 11, 2005 |
| Last update posted | Aug 24, 2018 |
| Countries | United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: